Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection

Nakano, Tadashi; Shimizu, Kamon; Kawashima, Osamu; Kamiyoshihara, Mitsuhiro; Nagashima, Tomomi; Igarashi, Takashi; Takeyoshi, Izumi

doi:10.1111/j.1365-2710.2011.01315.x

Cited by 13 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Landiolol is a highly adjustable β-blocker because it is administered intravenously and has a very short half-life of about four minutes. Nakano et al [11] also reported that continuous landiolol infusion is safe during open-heart surgery. In fact, none of the patients in Group L experienced severe hypotension or bradycardia that required discontinuation of landiolol therapy.…”

Section: Discussionmentioning

confidence: 98%

Safety of Landiolol Infusion in Patients Undergoing Lung Resection

Ito¹,

Nozaki²,

Sakamoto³

et al. 2014

OJAnes

View full text Add to dashboard Cite

The efficacy of landiolol hydrochloride, an ultrashort-acting β-blocker with high β1 selectivity, has been confirmed in patients undergoing cardiac surgery in Japan, but there have been few reports about its use for patients having lung resection. We investigated the safety of continuous infusion of landiolol in patients undergoing lung resection. Between May 2008 and May 2011, 200 patients scheduled for lung resection were enrolled. Patients who underwent surgery before the introduction of landiolol in February 2010 were studied retrospectively (Group C) and were compared with those who received landiolol along with surgery (Group L). During the 48-hour study period, the incidence of arrhythmias, changes in heart rate and blood pressure, and occurrence of adverse reactions were examined. The white blood cell count and C-reactive protein level were measured before and after surgery to assess the anti-inflammatory effect. The heart rate was significantly lower in Group L throughout the study period. No patient in Group L developed hypotension requiring discontinuation of landiolol therapy, and no respiratory symptoms (including asthma or hypoxemia) were observed. White blood cell and C-reactive protein were significantly increased after surgery in both groups, and there were no between-group differences. Arrhythmic events occurred in 1.1% (1/99) and 9.2% (7/76) of Group L and Group C, respectively. One patient in Group C developed ventricular tachycardia. Landiolol can be administered safely during the perioperative period in patients undergoing lung resection.

show abstract

Section: Discussionmentioning

confidence: 98%

Safety of Landiolol Infusion in Patients Undergoing Lung Resection

Ito¹,

Nozaki²,

Sakamoto³

et al. 2014

OJAnes

View full text Add to dashboard Cite

show abstract

“…A similar efficacy and good tolerance was revealed in two additional series of patients treated with landiolol. Control of heart rate was effective in 85% 29 and 92% 22 of patients. This was associated with a cardioversion to sinus rhythm in 56% (14/25) 29 and 77% (10/13).…”

Section: Landiolol Use To Control Heart Rate In Patients With Post-opmentioning

confidence: 96%

“…The landiolol dosages used in these series of patients were higher, applying loading dose of 60 mcg/kg/min followed by infusion of 10 mcg/kg/min titrated upwards to 40 mcg/kg/min 22 , 29 …”

Section: Landiolol Use To Control Heart Rate In Patients With Post-opmentioning

confidence: 99%

“…Experience with landiolol for prevention of AF in non-cardiac surgery is more documented than landiolol application for treatment of POAF. There are only limited trials 21 , 22 , 28 , 29 with total of 61 patients undergoing lung resection or oesophagectomy who developed POAF and were treated with landiolol to control heart rate. Conversely, there are nine comparative studies 22–27 , 30–32 with a total of 450 patients treated with landiolol for prevention of POAF.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Landiolol for managing post-operative atrial fibrillation

Borggrefe

Sander

Trimmel

et al. 2018

European Heart Journal Supplements

View full text Add to dashboard Cite

Beta-blockers are a potential option to manage peri-operative atrial fibrillation. Landiolol is a new ultra-short beta-blocker with a half-life of only 4 minutes and very high beta-1 selectivity which has been used for treatment and prevention of atrial fibrillation in pulmonary surgery and gastro-intestinal surgery. Due to its limited negative inotropic effect and high beta-1 selectivity landiolol allows for control of heart rate with minimal impact on blood pressure. Landiolol is well tolerated by the respiratory system. Additional benefits are related to the regulation of the inflammatory response and blunting of the adrenergic pathway. There is a limited number of trials with total of 61 patients undergoing lung resection or oesophagectomy who developed post-operative atrial fibrillation and were treated with landiolol. The experience with landiolol for prevention is more documented than landiolol application for treatment of post-operative atrial fibrillation. There are 9 comparative studies with a total of 450 patients administered landiolol for prevention of post-operative atrial fibrillation. The use of low dosage (5-10mcg/kg/min) is usually sufficient to rapidly control heart rate which is associated with earlier and higher rate of conversion to sinus rhythm as compared to the controls. The excellent tolerance of landiolol at lower dosage (3-5mcg/kg/min) allows to initiate prophylactic use during surgery and postoperatively. Landiolol prophylaxis is associated with reduced incidence of post-operative atrial fibrillation without triggering adverse events related to a beta-blockade.

show abstract

“…Landiolol has also been shown to be well tolerated in the critically ill for its limited negative inotropic effect and minimal impact on blood pressure [99][100][101]. The use of low doses (5-10 mcg kg -1 min -1 ) of landiolol is usually sufficient for the cardioversion of AF compared to controls.…”

Section: Beta-blockersmentioning

confidence: 99%

Management of arrhythmia in sepsis and septic shock

Borggrefe¹,

Matoušek²,

Malý³

et al. 2017

Anaesthesiol Intensive Ther

View full text Add to dashboard Cite

The occurrence of supraventricular arrhythmias is associated with an unfavourable prognosis in septic shock. Available trials are difficult to apply in sepsis and septic shock patients due to included cohorts, control groups and because "one size does not fit all". The priorities in the critically ill are maintenance of the sinus rhythm and diastolic ventricular filling. The rate control modality should be reserved for chronic AF and in situations when the sinus rhythm is difficult to maintain due to extreme stress conditions resulting from a high dosage of vasoactive agents. Electric cardioversion is indicated in unstable patients with an absence of contraindications and is more feasible in combination with an antiarrhythmic agent. Besides amiodarone being preferred for its lower cardiodepressant side effect compared to other agents, drugs with a different degree of betablocking activity are very useful in supraventricular arrhythmias and septic shock, providing echocardiography is routinely used to support their indications within the current summary of product characteristics. A typical patient benefiting from propafenone is without significant structural heart disease, i.e. typically with normal to moderately reduced left ventricular systolic function. Future research should be channelled towards echocardiography-guided prospective controlled trials on antiarrhythmic therapy which may clarify the issue of rhythm versus rate control, the effects of various antiarrhythmic drugs, and a place for electric cardioversion in critically ill patients in septic shock.

show abstract

Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection

Abstract: Continuous intravenous infusion of landiolol was found to be effective and safe for supraventricular tachycardia after pulmonary resection.

Cited by 13 publications

References 20 publications

Safety of Landiolol Infusion in Patients Undergoing Lung Resection

Safety of Landiolol Infusion in Patients Undergoing Lung Resection

Landiolol for managing post-operative atrial fibrillation

Management of arrhythmia in sepsis and septic shock

Contact Info

Product

Resources

About